[1] |
LU Renquan, LIU Guangyu, YANG Wentao, GUO Lin, GUAN Ming, SHAO Zhimin, XU Dazhi, NI Ming, TANG Feng, WANG Chaofu, LOU Jiatao, SUN Fenyong, XING Jinliang, PAN Yueyin.
Application consensus of peripheral blood HER2 gene amplification detection (digital PCR) in anti-HER2 therapy
[J]. China Oncology, 2022, 32(1): 90-96.
|
[2] |
FANG Yanhui , MA Caijuan , ZHANG Chunli , ZHAI Jiawei , ZHU Qiaoying , LIU Yin , ZHAO Xiwa .
miR-496 inhibits proliferation, migration and invasion of HeLa cell in cervical cancer via SFMBT1
[J]. China Oncology, 2021, 31(8): 697-703.
|
[3] |
LONG Xingtao , ZHOU Qi , WANG Dong , CHEN Yuemei , JIN Fujun .
The prognostic value of revised 2018 FIGO stage ⅢC in cervical cancer
[J]. China Oncology, 2021, 31(8): 725-733.
|
[4] |
ZHU Yihui, LI Ting, HU Xichun.
Clinical research progress and prospect of trastuzumab deruxtecan
[J]. China Oncology, 2021, 31(8): 754-761.
|
[5] |
DING Gaofeng, GUO Leiming, LU Yufei.
The relationship between expressions of HER2 and BRCA1 and radiotherapy sensitivity in breast cancer patients
[J]. China Oncology, 2021, 31(7): 589-595.
|
[6] |
DONG Shijie, HU Xiaoxin, WANG Wei, YANG Meng, YUE Lei, TONG Tong, GU Yajia.
Prediction of lymph node metastasis of cervical cancer based on multi-sequence MRI and multi-system imaging omics model
[J]. China Oncology, 2021, 31(6): 460-467.
|
[7] |
ZHU Jun, WU Xiaohua.
Leading research progress and prospect of gynecological oncology in 2020
[J]. China Oncology, 2021, 31(4): 250-256.
|
[8] |
GUO Ye , ZHANG Chenping .
Expert consensus on the treatment of recurrent/metastatic squamous cell carcinoma of the head and neck with anti-EGFR monoclonal antibody (2021 edition)
[J]. China Oncology, 2021, 31(12): 1220-1232.
|
[9] |
PAN Jian, WEI Yu, YE Dingwei, ZHU Yao.
Correlation between EGFR (rs884419) gene polymorphism and clinicopathological characteristics of prostate cancer
[J]. China Oncology, 2021, 31(11): 1104-1109.
|
[10] |
HE Xi, JIAO Xiaodong, ZANG Yuansheng.
Clinical research progress of tumor mutational burden in EGFR-mutant advanced non-small cell lung cancer
[J]. China Oncology, 2021, 31(1): 69-75.
|
[11] |
ZHU Lihua , NI Tingting , FAN Xingwen , WU Kailiang .
Comparison of prognostic scoring systems in patients with EGFR-mutant lung cancer and brain metastases
[J]. China Oncology, 2020, 30(8): 605-610.
|
[12] |
SHI Zhiqiang , QIU Pengfei , LIU Yanbing , ZHAO Tong , SUN Xiao , CHEN Peng , WANG Chunjian , ZHANG Zhaopeng , CONG Binbin , WANG Yongsheng .
Selective elimination of axillary surgery staging after neoadjuvant chemotherapy for HER2 positive and triple-negative breast cancer
[J]. China Oncology, 2020, 30(3): 186-191.
|
[13] |
SHEN Jie , MO Miao , YUAN Jing , ZHOU Changming , WANG Zezhou , ZHANG Zhihong , WEN Hao , WU Xiaohua , ZHENG Ying .
Long-term survival report on 1 313 patients with locally advanced cervical cancer: a hospital-based real world study
[J]. China Oncology, 2020, 30(3): 192-198.
|
[14] |
CHEN Xiaohui, WANG Jiazhou, HU Weigang, PENG Jiayuan, ZHAI Peng.
Dosimetric impact of machine and treatment planning system on knowledge-based planning: a study based on cervical cancer IMRT plan
[J]. China Oncology, 2020, 30(10): 821-825.
|
[15] |
WANG Li,REN Yulan,WANG Huaying .
Pulmonary embolism after radical surgery of cervical cancer: a case report and the review of literature
[J]. China Oncology, 2019, 29(8): 599-601.
|